Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. by Singh, Ajay P. et al.
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Journal Articles: Biochemistry & Molecular 
Biology Biochemistry & Molecular Biology 
1-18-2008 
Genome-wide expression profiling reveals transcriptomic variation 
and perturbed gene networks in androgen-dependent and 
androgen-independent prostate cancer cells. 
Ajay P. Singh 
University of Nebraska Medical Center 
Sangeeta Bafna 
University of Nebraska Medical Center 
Kunal Chaudhary 
University of Nebraska Medical Center 
Ganesh Venkatraman 
University of Nebraska Medical Center 
Lynette Smith 
University of Nebraska Medical Center, lmsmith@unmc.edu 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unmc.edu/com_bio_articles 
 Part of the Medical Biochemistry Commons, and the Medical Molecular Biology Commons 
Recommended Citation 
Singh, Ajay P.; Bafna, Sangeeta; Chaudhary, Kunal; Venkatraman, Ganesh; Smith, Lynette; Eudy, James D.; 
Johansson, Sonny L.; Lin, Ming-Fong; and Batra, Surinder K., "Genome-wide expression profiling reveals 
transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent 
prostate cancer cells." (2008). Journal Articles: Biochemistry & Molecular Biology. 33. 
https://digitalcommons.unmc.edu/com_bio_articles/33 
This Article is brought to you for free and open access by the Biochemistry & Molecular Biology at 
DigitalCommons@UNMC. It has been accepted for inclusion in Journal Articles: Biochemistry & Molecular Biology 
by an authorized administrator of DigitalCommons@UNMC. For more information, please contact 
digitalcommons@unmc.edu. 
Authors 
Ajay P. Singh, Sangeeta Bafna, Kunal Chaudhary, Ganesh Venkatraman, Lynette Smith, James D. Eudy, 
Sonny L. Johansson, Ming-Fong Lin, and Surinder K. Batra 
This article is available at DigitalCommons@UNMC: https://digitalcommons.unmc.edu/com_bio_articles/33 
Genome-wide Expression Profiling Reveals Transcriptomic
Variation and Perturbed Gene Networks in Androgen-dependent
and Androgen-independent Prostate Cancer Cells
Ajay P. Singh1, Sangeeta Bafna1, Kunal Chaudhary1, Ganesh Venkatraman1, Lynette
Smith2, James D. Eudy3, Sonny L. Johansson4,5, Ming-Fong Lin1,5, and Surinder K.
Batra1,5,*
1Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center,
Omaha, Nebraska
2Department of preventive and Societal Medicine, University of Nebraska Medical Center, Omaha,
Nebraska
3Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center,
Omaha, Nebraska
4Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha,
Nebraska
5Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical
Center, Omaha, Nebraska
Abstract
Previously, we have developed a unique in vitro LNCaP cell model, which includes androgen-
dependent (LNCaP-C33), androgen-independent (LNCaP-C81) and an intermediate phenotype
(LNCaP-C51) cell lines resembling the stages of prostate cancer progression to hormone
independence. This model is advantageous in overcoming the heterogeneity associated with the
prostate cancer up to a certain extent. We characterized and compared the gene expression profiles
in LNCaP-C33 (androgen-dependent) and LNCaP-C81 (androgen-independent) cells using
Affymetrix GeneChip array analyses. Multiple genes were identified exhibiting differential
expression during androgen-independent progression. Among the important genes upregulated in
androgen-independent cells were PCDH7, TPTE, TSPY, EPHA3, HGF, MET, EGF, TEM8, etc.,
whereas many candidate tumor suppressor genes (HTATIP2, CDKN2A, CDKN2B, CDKN1C, TP53,
TP73, ICAM1, SOCS1/2, SPRY2, PPP2CA, PPP3CA, etc.) were decreased. Pathway prediction
analysis identified important gene networks associated with growth-promoting and apoptotic
signaling that were perturbed during androgen-independent progression. Further investigation of one
of the genes, PPP2CA, which encodes the catalytic subunit of a serine phosphatase PP2A, a potent
tumor suppressor, revealed that its expression was decreased in prostate cancer compared to adjacent
normal/benign tissue. Furthermore, the downregulated expression of PPP2CA was significantly
correlated with tumor stage and Gleason grade. Future studies on the identified differentially-
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expressed genes and signaling pathways may be helpful in understanding the biology of prostate
cancer progression and prove useful in developing novel prognostic biomarkers and therapy for
androgen-refractory prostate cancer.
Keywords
Prostate Cancer; Gene expression; Transcriptomic variation; Androgenin-independence; Gene-
networks
INTRODUCTION
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of
cancer death in men in the United States [1]. It has been estimated that 218,890 new cases of
prostate cancer will be diagnosed and 27,050 people will die due to prostate cancer in the year
2007 [1]. Clinical progression of prostate cancer is characterized by a transition from an
androgen-dependent (AD) to an androgen-independent (AI) phenotype. Most patients treated
by androgen deprivation therapy initially exhibit a dramatic regression of the androgen-
dependent cancer cells; however, the tumor eventually progresses to an androgen-independent
stage, resulting in a poor prognosis [2]. Therefore, an improved understanding of the molecular
mechanisms underlying the AI progression of prostate cancer is required to develop novel
effective therapies.
Initial insight into the molecular nature of prostate cancer progression can be gained by
examining the gene expression patterns associated with AD and AI phenotypes. Prostate
cancer, however, poses significant challenges to this approach due to the heterogeneity of
primary and metastatic tumors [3]. To overcome this limitation, we have developed an in-
vitro prostate cancer progression model consisting of early passage AD (LNCaP-C33), late
passage AI (LNCaP-C81) and an intermediate-phenotype (LNCaP-C51) cell lines [4]. This
model closely resembles with different progressive stages to hormone-independency and has
been used previously to understand the disease mechanisms [4–6].
In this study, we have performed a genome-wide expression profiling and pathway prediction
analyses in AD and AI prostate cancer cells to characterize the transcriptomic variation and
identify the perturbed gene networks associated with the prostate cancer progression. Our study
provides a list of candidate genes that could be useful for the development of new diagnostic/
prognostic markers for human prostate cancer. Furthermore, it reveals that the androgen-
independent progression of prostate cancer mainly involves a repression of cell signaling
pathways. Functional studies on the identified differentially-expressed genes may be helpful
in understanding the biology of prostate cancer progression and prove useful in developing
novel treatment for androgen-refractory prostate cancer.
Materials and Methods
Cancer cell lines and tissue specimens
Human prostate cancer cell lines (LNCaP-C33, LNCaP-C81, LNCaP-C4-2, PC3 and DU145)
were utilized in the study. LNCaP-C33 (androgen-sensitive) and LNCaP-C81 (androgen-
independent) cell lines are of same genotypic lineage and serve as a good model for prostate
cancer progression [4]. Furthermore, LNCaP cells express functional androgen receptors as is
the case in majority of prostate carcinomas. All cell lines were maintained in the ATCC
specified culture media supplemented with 10% FBS and 100µg/ml of penicillin-streptomycin
(Gibco BRL, Grand Island, NY). Growth media were changed alternate days and the cells were
trypsinized at near confluence. Prostate cancer tissue microarray containing 2 spots each from
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35 cancer cases (formalin-fixed and paraffin-embedded) along with 1 spot from adjacent
normal/benign tissue were obtained from a commercial source (Accumax™ Array, Petagen
Inc., Seoul, Korea).
RNA isolation
Total RNA was extracted from cancer cell lines by using guanidine isothiocyanate-cesium
chloride ultracentrifugation method and/or by using an RNeasy RNA isolation kit (Qiagen Inc.,
Valencia, CA). RNA concentration was measured spectrophotometrically, and its integrity was
analyzed by electrophoresis on a formaldehyde agarose gel.
Affymetrix GeneChip array analysis
The mRNA expression profiles of LNCaP-C33 and -C81 cells were examined by Affymetrix
Genechip microarray (Affymetrix, Santa Clara, CA, USA). Total RNA (5 µg) was reverse-
transcribed, and biotin-labeled cRNA probes were generated using the Affymetrix labeling kit
as per manufacturer’s instructions. Biotinylated fragmented cRNA probes were hybridized to
the HGU133 plus2 Genechips (Affymetrix). Hybridization was performed at 45°C for 16 h in
a hybridization oven (Affymetrix). The Genechips were then automatically washed and stained
with streptavidin–phycoerythrin conjugate in an Affymetrix Genechip Fluidics Station.
Fluorescence intensities were scanned using the Affymetrix GeneChip 3000 scanner in the
UNMC microarray core facility. Quality metric parameters including noise level, background,
and the efficiency of reverse transcription were ascertained for all hybridizations. The resultant
microarray datasets were scaled to a target signal intensity of 500 using Affymetrix GCOS
software. To identify differentially expressed genes and associated fold-change differences,
the scaled intensities were compared to each other using Affymetrix comparison analysis
software.
Pathway analysis
Pathway prediction analysis on the differentially expressed genes was performed using a web-
based application ‘Ingenuity Pathway Analysis’ (Ingenuity Systems, Mountain View, CA).
This web-delivered application searches its database to place differentially expressed genes in
gene clusters linked to a molecular pathway(s) and is helpful in postulating the functional
assumption from the large amount of gene expression data.
Quantitative reverse transcription-polymerase chain reaction (Q-RT-PCR)
Total RNA (2µg) from each of the prostate cancer cell line was reverse transcribed using the
first-strand cDNA synthesis kit (Perkin Elmer, Branchburg, NJ) and oligo-d(T) primers
according to the manufacturer’s instructions. Real-time PCR amplifications were carried out
with 100 ng of first strand cDNA in 10-µl reaction volumes. The reaction mixture was subjected
to a two step cyclic program (95°C for 10 min. followed by 40 cycles of 95°C for 15 sec. and
60°C for 1 min.) as per manufacturer’s protocol on ABI 7500 sequence detection system
(Applied Biosystems, Foster City, CA) with SYBR chemistry. Pre-designed PCR primers for
SPRY2, ALCAM, TPTE, HGF, MET, PTK6, PCDH7 and GAPDH were purchased from a
commercial source (Superarray Biosciences Corporation, Frederick, MD). The relative fold
difference in gene expression was calculated by ǻǻCT method [7] using GAPDH as
normalization control.
Western-blot analysis
Total protein was extracted from prostate cancer cell lines, resolved and analyzed by western
blotting as previously described [8]. In brief, cells were washed with cold-phosphate buffered-
saline (PBS), scraped in RIPA buffer (100 mM Tris, 5 mM EDTA, 5% NP40, pH-8.0)
containing protease inhibitors cocktail (Roche diagnostics, Mannheim, Germany) and allowed
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for lysis for at least 30 min on ice with intermittent vortexing. Cells were subjected to further
lysis by one freeze-thaw cycle and centrifuged at 14,000×g for 30 min at 4°C. Supernatants
were carefully removed and protein concentrations were determined by Bio-Rad-DC protein
estimation kit. Electrophoresis was performed on polyacrylamide gel (10%) using equal
amounts of protein samples under reducing conditions. Resolved proteins were transferred to
the PVDF membranes and probed with specific primary antibodies [anti-PP2A rabbit Mab,
Clone Y119 (Epitomics, Inc., Burlingame, California); anti-PGK rabbit polyclonal antibodies
(a gift from Dr. J.K. Vishwanatha, UNMC)] followed by incubation with corresponding
horseradish peroxidase-conjugated secondary antibodies (Amarsham Biosciences
Buckinghamshire, UK). Signal was detected with ECL electro-chemiluminescence (ECL) Kit
(Amarsham Biosciences).
Immunohistochemistry
Tissue microarray sections were deparaffinized using EZ-DeWax™ (Bio Genex, San Ramon,
CA) and then rehydrated with graded alcohols. Heat-induced antigen retrieval was performed
in citrate buffer (pH 6.0) by heating slides in a microwave oven at 700 W for 15 min. and the
sections were processed for immunohistochemistry as described previously [8]. In brief, the
tissue sections were washed three times with phosphate buffered saline (PBS) and incubated
with 0.3% H2O2 in methanol: PBS (1:1) solution for 30 min to quench the endogenous
peroxidase activity. Slides were then washed with PBS and incubated with normal serum
(Vectastain ABC kit, Vector Laboratories, Burlingame, CA) for 30 min. for blocking the non-
specific immunostaining. The sections were then incubated with a 1:100 dilution of anti-PP2A
antibody at room temperature for one hour. Slides were washed (3 × 5 min) with PBS containing
0.05% Tween-20 (PBS-T) and incubated with biotinylated- secondary antibody for 30 min.
After washing (3 × 5 min) with PBS-T, the slides were incubated with ABC solution (Vector
Laboratories) at room temperature. The reaction color was developed by treating the tissue
sections with 3, 3 –diaminobenzidine (DAB) substrate (DAB substrate kit, Vector
Laboratories) as per the manufacturer's instructions. A reddish-brown precipitate indicated
positive immunoreactivity. The slides were washed with water, counter-stained with
hematoxylin, dehydrated and mounted with Vectamount permanent mounting media (Vector
Laboratories).
Assessment of antigen staining
All slides were analyzed using a Nikon Eclipse E400 Microscope (Japan) and the intensity of
immunoreactivity was scored. Staining intensity was graded on a 0 to 3 scale (0 for no staining,
+ for weak immunoreactivity; ++ for moderate immunoreactivity; and +++ for strong
immunoreactivity). The percentage of cells that showed positive immunoreactivity within the
normal epithelial/cancerous region of the section was scored as follows: 1 for 0–25%; 2 for
26–50%; 3 for 51–75%; and 4 for 76–100%. The values of the staining intensity and the percent
of immunoreactive cells were multiplied to obtain a composite score ranging from 0–12
Statistical analysis
Paired t-tests were used to see if there was significant difference in the composite score values
of PP2A, when comparing benign and prostate cancer samples.
RESULTS
A genome-wide survey of differentially-expressed genes in androgen dependent versus
androgen-independent prostate cancer cells
Progression of prostate cancer from an AD phenotype to AI nature may involve alterations in
the expression of multiple genes. To identify these genes, we aimed at characterizing and
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comparing the genome-wide expression profiles in LNCaP-C33 (AD) and LNCaP-C81 (AI)
prostate cancer cells. LNCaP human prostate cancer cell model was employed because this
model recapitulate many characteristics associated with progression of prostate cancer cells
from AD to androgen-refractory phenotype [4].
Total RNA was extracted from the cell lines and analyzed using Affymetrix Genechips (Human
Genome U133plus2 GeneChip) to determine the global gene expression patterns. The Human
Genome U133plus2 GeneChip contains greater than 54,000 probe sets and can be used to
analyze the expression level of more than 47,000 transcripts and variants, including
approximately 38,500 well-characterized human genes. Over 2,000 probe sets were determined
to be differentially expressed (with equal to and/or more than two-fold difference) in LNCaP-
C33 vs. LNCaP-C81 cells (data not shown). Notably, in our study, more differentially-
expressed genes were found to be under-expressed (n=1460) than upregulated (n=876) in AI
prostate cancer cells. Table 1 and Table 2 present the list of some of the selected genes over-
expressed and under-expressed, respectively, during the AI growth of LNCaP prostate cancer
cells. We have selected these genes based on their fold-change in expression, comparison with
the Oncomine cancer profiling database (www.oncomine.org) and established pathological
significance in prostate and/or other cancers.
Validation of Affymetrix data by quantitative reverse transcriptase–polymerase chain
reaction
To confirm that gene expression changes observed in microarray analysis were indeed
associated with androgen-independent phenotype, we examined the expression of a few select
genes by quantitative real-time reverse transcription–polymerase chain reaction (RT–PCR)
(Figure 1). Consistent with the GeneChip data, Q-RT–PCR confirmed an increased expression
of PCDH7, HGF, Met, and TPTE and a decreased expression of ALCAM, SPRY2 and PTK6
in AI (LNCaP-C81) cells after normalizing the data with that of a housekeeping gene,
glyceraldehyde-3-phophate dehydrogenase (GAPDH).
Identification of signaling pathways associated with the progression of prostate cancer cells
toward an androgen-refractory phenotype
To identify the genetic networks altered during the androgen-refractory progression of prostate
cancer cells, we utilized microarray data to perform a pathway prediction analysis using web-
based application ‘Ingenuity pathway analysis’ (Ingenuity Systems, Mountain View, CA). This
web-delivered soft-ware searches its database to place differentially expressed genes in gene
clusters linked to a molecular pathway(s). We identified several genetic networks to be
perturbed during androgen-independent progression (Table 3). Most of the signaling pathways
central to the identified gene networks were found to be suppressed, except EGF, HGF and
E2F4 (Table 3). Thus, our data suggest that the prostate cancer mainly involves a repression
of cell signaling pathways to attain an androgen-refractory phenotype.
Immunohistochemical analyses of protein phosphatase 2, catalytic subunit, (PPP2CA) in
prostate cancer
Genome-wide survey of the differential gene expression resulted in the identification of
multiple genes with potential pathobiological importance in androgen-refractory progression
of prostate cancer. From the long list of genes, we chose PPP2CA for further analysis at protein
level in human prostate cancer tissues to predict its prospective significance. PPP2CA encodes
the catalytic subunit (alpha-isoform) of protein phosphatase 2A (PP2A), which is a serine
phosphatase implicated in the negative control of the cell division and survival. Immunoblot
analysis demonstrated its variable expression pattern in AD and AI prostate cancer cell lines
(Figure 2). Consistent with the microarray data, PP2A was downregulated in LNCaP-C81 (AI)
cells compared to the LNCaP-C33 (AD) cells. Furthermore, data from immunohistochemical
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analysis also showed an overall downregulation of PP2A in cancer lesions compared to the
adjacent normal/benign tissue (Figure 3). Out of the 35 human tissue samples, 22 (62.9%)
showed positive reactivity in normal/benign region, whereas only 20 (57.0%) cancer cases
were positive for PP2A (Table 4). No intense immunoreactivity was observed in either normal/
benign or cancer cells. Composite score values for normal/benign cells ranged from 0 to 6 with
a mean composite score of 1.6. In cancer cells, however, the composite score values ranged
from 0 to 3 (mean composite score=0.7) due to less number of immunoreactive cells (%
positivity). The difference between mean composite scores of benign and cancer samples was
statistically significant (P=0.0073). Interestingly, when we compared the composite score
differences in the stage and Gleason grade subgroups, the composite score were significantly
greater in late stage [stages 3 & 4] (P=0.015) and high Gleason grade [Gleason score 8–10]
(P=0.042) subgroups as compared to early stage and low Gleason grade subgroups,
respectively.
DISCUSSION
The present study examined the differential gene expression in androgen-dependent (AD)
LNCaP-C33 and androgen-independent (AI) LNCaP-C81 cells via genome-wide expression
profiling. Our study resulted in the identification of many key genes that could be of clinical
importance and future targets for prostate cancer therapy. Furthermore, our data indicated that
the androgen-refractory progression of prostate cancer mainly involves a repression
mechanism as a majority of the differentially-expressed genes and signalling networks were
downregulated in AI prostate cancer cells.
Over the last decade, DNA array technique has contributed significantly in identifying novel
molecules that play potential role in the disease progression as well as in the classification of
various cancers [9–11]. Moreover, recent technological advances have enabled the
comprehensive surveying of a cell’s transcriptional landscape. Genome-wide analysis allows
the simultaneous monitoring of whole transcriptome, and is helpful in identifying the functional
and biochemical pathway(s) that are perturbed during the disease progression and targeted by
the therapeutic drugs [12;13]. In prostate cancer, several studies have been conducted on
different types of DNA arrays using tumor biopsy specimens, tumor cell lines, and more
recently tissues obtained from rapid autopsies [14;15]. What we have learnt thus far is that
prostate cancer is a heterogeneous group of diseases [3] and therefore a crucial examination
of current or newly identified biomarkers is needed, while considering their potential as
diagnostic, prognostic and therapeutic targets.
In this study, we utilized a unique in vitro LNCaP cell model, which includes different LNCaP
cells (AD: C33 and AI: C81), closely resembling early and late stages of tumor progression
[4]. One advantage of using this model is that it overcomes the heterogeneity, associated with
the prostate cancer [3] to a certain extent. Furthermore, LNCaP cells express functional
androgen receptors as is the case in majority of prostate carcinomas. We hypothesized that
identification of differentially regulated genes between AD (C33) and AI (C81) prostate cancer
cells may provide insights into its clinical course of progression and may be exploited for a
variety of clinical applications. Genome-wide expression analysis generated a large amount of
interesting data and identified many genes that were differentially regulated in AI prostate
cancer cells. Genes identified in our study include those involved in cell proliferation,
apoptosis, angiogenesis, hormone response, etc. These genes are of potential interest for
follow-up studies. While some have already been reported to have potential as clinical
biomarkers [15–17], many others seem to be novel in context to their association with AI
phenotype. Among the selected overexpressed genes in androgen-independent (C81) cells, two
(TPTE and TSPY) have previously been shown to exhibit a testis-specific restricted pattern of
expression in normal conditions [18;19]. TPTE (transmembrane phosphatase with tensin
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homology) encodes a PTEN-related tyrosine phosphatase (also referred as PTEN2) with four
potential transmembrane domains [19]. PTEN (phosphatase and tensin homolog) acts as a
tumor suppressor and its multiple implications in prostate cancer progression have also been
reported [20]. No clear biological function has yet been assigned to TPTE and future studies
are warranted to understand its role in tumor progression. In contrast to our finding, another
study has reported recurrent loss of a gene cluster on Y-chromosome involving TSPY (tumor-
specific protein-Y linked) in prostate cancer [21]. This further supports the heterogeneous
nature of AI prostate cancer as previously described [3] and suggests the existence of different
signaling mechanisms among subtypes of metastatic prostate cancer. Nonetheless, a recent
study has shown the oncogenic potential of TSPY in Hela and NIH3T3 cells [22]. Other
important overexpressed genes were HGF (hepatocyte growth factor) and MET/HGFR
(hepatocyte growth factor receptor). HGF and its receptor, c-Met, have been demonstrated to
elicit a number of key functions in numerous tissues that are important in the progression,
invasion and metastasis of cancer [23]. Involvement of HGF-Met signalling in metastatic
prostate cancer development has also been reported [24].
It is interesting to note that relatively more differentially-expressed genes were found to be
under-expressed (n=1460) than overexpressed (n=876) in AI prostate cancer cells (data not
shown). In our study, Angiopoietin 2 (ANGP2), whose expression has been shown to correlate
with increasing grade of prostate cancer [25], was found to be downregulated in AI prostate
cancer cells. Thrombospondin 1 (THBS1) is another important gene that was highly repressed
in AI prostate cancer cells. In previous studies, it has been shown to possess anti-angiogenic
activity [26–28]. The intratumoral administration of a THBS1 expression vector into androgen-
independent DU-145 prostate cancer xenografts was shown to inhibit tumor growth in vivo
through inhibition of tumor angiogenesis [28]. Interestingly, androgens have been shown to
repress the expression of thrombospondin 1 in normal and neoplastic prostate tissues [27].
HTATIP2, another tumor and metastasis suppressor gene [29], was also repressed in androgen-
refractory PC cells. Ectopic expression of HTATIP2 in v-SCLC cells induced expression of a
number of genes including the apoptosis-related genes Bad and Siva, as well as metastasis
suppressor NM23-H2 [30]. SPRY2, an inhibitor of receptor tyrosine kinase (RTK) signaling,
found to be under-expressed in our study has been shown to be epigenetically inactivated in
prostate cancer [31]. Progressive loss of ALCAM, which is downregulated in AI prostate cancer
cells, has been reported in high-grade prostate carcinomas [32]. Among other genes of
importance exhibiting downregulated expression in AI prostate cancer cells were CDKN2B/
TP53, CDKN1C/TP57, TP73. These genes are known tumor suppressors and are frequently
silenced in cancers [33–35].
To better understand the functional premise related to androgen-independent progression, we
searched for patterns of gene expression using Ingenuity pathway analysis. Many signaling
networks (Table 3) were identified, suggesting that perturbation of these molecular pathways
is associated with the gain of androgen-refractory phenotype. In the literature, these pathways
have been shown to be linked with various aspects of tumor progression [36–40]. Of particular
interest is the finding that most of the pathways identified in our analysis were repressed in
androgen-refractory prostate cancer cells. Importantly, many (TP53, TP73, p16, and TRAIL)
among these downregulated pathways are associated with growth inhibitory cell signaling.
PPP2CA, which encodes for the catalytic-subunit (alpha-isoform) of the protein phosphatase
2A (PP2AC), was one of several genes of interest that exhibited a downregulated expression
in our analysis in AI prostate cancer cells. PP2A is a potent tumor suppressor and is involved
in broad cellular functions [41]. In light of recent observations, it seems to be of potential
interest in prostate cancer [42–45]. Data mining analysis using Oncomine cancer profiling
database (www.oncomine.org) demonstrate that PPP2CA is significantly downregulated in
prostate cancer compared to normal/benign prostate (4 studies) and in metastatic prostate
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cancer compared to primary prostate carcinoma (3 studies). Interestingly, in a recent report the
expression of the beta-isoform of catalytic-subunit of PP2A (PPP2CB) is also shown to be
downregulated in prostate cancer [43]. Our immunohistochemical analysis in normal/benign
and matched prostate cancer tissues corroborated the downregulated expression of PP2A in
prostate cancer. However, we were not able to obtain patient-matched, androgen-dependent
and androgen-independent specimens to examine the expression of PP2A during progression
to AI phenotype.
In summary, our study offers a significant contribution to our knowledge of the molecular
characteristics of AI prostate cancer. Overall comparison of the expression data between AD
and AI prostate cancer cells is intriguing demonstrating the decreased expression of several
tumor suppressor genes in the AI tumor cells, while many genes that may potentially promote
growth and metastasis were upregulated. Protein phosphatase 2A was identified as
differentially-expressed protein and its downregulated expression may be of potential
importance during the prostate cancer development and further during AI progression of the
disease. Many of these differentially-expressed genes may be important as potential diagnostic/
prognostic and therapeutic targets for the prostate cancer.
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Figure 1.
Expression analysis of differential gene expression by real-time RT-PCR. Total RNA was
reverse-transcribed and subsequently amplified by a real-time PCR using gene-specific
primers. A fold-change in expression was calculated relative to LNCaP-C33 cells using
GAPDH as an internal control by ǻǻCT method. Each experiment was repeated at least three
times and data presented as mean ± standard deviation.
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Figure 2.
Immunoblot analysis of PPP2CA (alpha isoform of catalytic subunit of protein phosphatase
2A). Consistent with the microarray analysis, a reduced expression of PPP2CA is observed in
androgen-independent (AI) LNCaP-C81 cells compared to androgen-dependent (AD) LNCaP-
C33 cells. Except DU145, a reduced expression of PPP2CA is also evident in other AI cell
lines (C4-2 and PC3). Phospho-glycerol kinase (PGK) was used as an internal control.
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Figure 3.
Immunohistochemical analysis of PPP2CA expression on a prostate cancer tissue array. A and
B, Normal/benign tissue at 10X and 40 × magnifications, respectively. C, Prostate cancer
section with various grade lesions (10× magnification), D and E, magnified (40X) view of
section depicting lesions with Gleason grade 6 (3+3) and 8 (4+4), respectively. A decreased
expression of PPP2CA is observed in prostate cancer, which further correlates with Gleason
grade.
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Table 1
List of selected genes that are overexpressed in androgen-independent (LNCaP-C81) compared to androgen-
dependent (LNCaP-33) prostate cancer cells.
Gene Product Fold-change
(Logbase2)
Function Genomic
location
PCDH7 Protocadherin 7 7.9 Cell adhesion 4p15
NRXN3 Neurexin 3 7.7 " 14q31
TPTE/
PTEN2
Transmembrane phosphatase with tensin
homology
5.4 Signal transduction 21p11
EPHA3 EPH receptor A3 5.3 " 3p11.2
TSPY Testis specific protein, Y-linked 4.5 Hormone-response Yp11.2
HGF Hepatocyte growth factor 4.4 Signal transduction 7q21.1
PKIA Protein kinase inhibitor alpha 4.4 " 8q21.12
PRLR Prolactin receptor 3.8 " 5p14-p13
NR2F1 Nuclear receptor subfamily 2, group f,
member 1
3.6 Hormone-response 5q14
TNS Tensin 3.6 Signal transduction, cell migration 2q35-q36
MET Hepatocyte growth factor receptor 3.2 Signal transduction 7q31
CALN1 Calneuron 1 3.2 Calcium-binding protein 7q11
ADAM-TS3 A disintegrin and metalloprotease with
thrombospondin motifs-3
3.1 propeptidase 4q13.3
NPL4 Nuclear protein localization 4 3 Protein trafficking 17qter
MYO3A Myosin IIIA 3 Actin-dependent motor protein 10p11.1
GNA11 Guanine nucleotide binding protein (G
protein), alpha 11
2.8 Signal transduction 19p13.3
GAGEB1/PA
GE1
P antigen family, member 1 (prostate
associated)
2.7 Tumor-linked protein, function
unknown
Xp11.23
AKAP9 A kinase anchor protein 1 2.6 Signal transduction 17q21-q23
TCF4 Transcription factor 4 2.6 " 18q21.1
MYLK Myosin, light polypeptide kinase 2.6 cell migration 3q21
KLK2 Kallikrein 2 2.4 peptidase 19q13.41
HOXA10 Homeo box A10 2.3 Signal transduction 7p15-p14
DDR2 Discoidin domain receptor family, member 2 2.2 " 1q12-q23
EGF Epidermal growth factor 2.2 Cell growth 4q25
TEM8 Tumor endothelial marker 8 2.1 angiogenesis 2p13.1
XAGE-1 X antigen family, member 1 2 Cancer/testis-associated gene,
unknown function
Xp11.22-p11.21
GAS2 Growth arrest-specific 2 2 Regulation of cell shape, apoptosis 11p14.3-p15.2
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Table 2
List of selected genes that are under-expressed in androgen-independent (LNCaP-C81) compared to androgen-
dependent (LNCaP-33) prostate cancer cells.
Gene Product Fold-
change
(Logbase2)
Function Genomic
location
ANGPT2 Angiopoietin 2 7.8 Context-dependent vascular regression and angiogenesis 8p23.1
THBS1 Thrombospondin 1 7.3 Cell-cell and cell-extracellular matrix interaction 15q15
CCL5 Chemokine (c-c motif) ligand 5 6.2 Chemokine, immunoregulatory 17q11.2-12
PTK6 Protein tyrosine kinase 6 6.1 Signal transduction 20q13.3
CXCL11 Chemokine (c-x-c motif) ligand 11 5.8 Chemokine, immunoregulatory 4q21.2
S100P S100 calcium binding protein p 5.1 Hormone response 4p16
PSMD5 Proteasome 26s non-ATPase subunit, 5 4.9 Multi-subunit protease 9q33.2
CDKN2B Cyclin-dependent kinase inhibitor 2b 4.7 tumor suppressor 9p21
PEG3 Paternally expressed 3 4.5 " 19q13.4
HTATIP2 Hiv-1 tat interactive protein 2 4.4 " 11p15.1
CXCL2 Chemokine (c-x-c motif) ligand 2 4.4 Chemokine, immunoregulatory 4q21
RND1 Rho family gtpase 1 4.2 Cell motility 12q12-q13
NK4 Natural killer4/Interleukin 32 4.1 cytokine 16p13.3
ACPP Prostatic acid phosphotase 4.1 Hormone response, growth signaling 3q21-q23
ICAM1 Intercellular adhesion molecule 1 4 tumor suppressor, cell migration 19p13.3-13.2
FOSL2 Fos-like antigen 2 3.9 Cell proliferation/differentiation 2p23.3
SFN Stratifin 3.7 Tumor suppressor 1p36.11
PLAT Plasminogen activator, tissue 3.5 Cell migration, tissue remodeling 8p12
INHBE Inhibin, beta E 3 tumor suppressor 12q13.3
CDKN1C Cyclin-dependent kinase inhibitor 1c 2.9 tumor suppressor 11p15.5
TP73 Tumor protein p73 2.7 tumor suppressor 1p36.3
SOCS2 Suppressor of cytokine signaling 2 2.7 growth suppressor 12q
BMPR1B Bone morphogenetic protein receptor, type 1B 2.7 Signal transduction 4q22-q24
CCL2 Chemokine (c-c motif) ligand 2 2.6 chemokine 17q11.2-q21.1
VIM Vimentin 2.6 Mesenchymal cytoskeletal protein 10p13
SPRY2 Sprouty 2 2.6 tumor suppressor 13q31.1
CXCL10 Chemokine (c-x-c motif) ligand 10 2.6 Chemokine, angiostatic 4q21
LCN2 Lipocalin 2 2.5 Tumor suppressor/promoter 9q34
AKAP12 A kinase anchor protein 12 2.4 tumor/metastasis suppressor 6q24-q25
KLF4 Kruppel-like factor 4 2.4 Transcriptional activator 9q31
ATF3 Activating transcription factor 3 2.4 apoptosis, cell migration 1q32.3
FBN1 Fibrillin 1 2.4 ECM protein, cell attachment 15q21.1
TWIST1 Twist homolog 1 2.4 Invasion, metastasis 7p21.2
ALCAM Activated leukocyte cell adhesion molecule 2.3 Cell adhesion 3q13.1
MSX2 Msh homeo box homolog 2 2.2 tumor suppressor 5q34-q35
LOX Lysyl oxidase 2.2 Cross-linking of ECM proteins 5q23.2
BTG1 B-cell translocation gene 1 protein 2.2 Hormone response, anti-proliferative 12q22
SOCS1 Suppressor of cytokine signaling 1 2.2 tumor suppressor 16p13.13
PPP2CA Protein phosphatase 2 (formerly 2a), catalytic
subunit, alpha isoform
1.5 Serine phosphatase, control of cell
division
5q23-q31
PPP3CA Protein phosphatase 3 (formerly 2b), catalytic
subunit, alpha isoform
1.3 Serine phosphatase, apoptosis 4q21-q24
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